Multivariate explanatory model for sporadic carcinoma of the colon in Dukes’ stages I and IIa by Villadiego Sánchez, José María et al.
Int. J. Med. Sci. 2009, 6 
 
 
http://www.medsci.org 
43
International Journal of Medical Sciences 
2009; 6(1):43-50 
© Ivyspring International Publisher. All rights reserved 
Research Paper 
Multivariate explanatory model for sporadic carcinoma of the colon in 
Dukes’ stages I and IIa 
J.M. Villadiego-Sánchez1, M. Ortega-Calvo2 , R. Pino-Mejías3, A. Cayuela4, P. Iglesias-Bonilla2, F. Gar-
cía-de la Corte2, J.M. Santos-Lozano2, and José Lapetra-Peralta2  
1. 061 Accident and Emergency Service. Huelva. Spain.  
2. Department of Family Medicine, Primary Care Division of Seville and CIBER Fisiopatologia Obesidad y Nutrición 
(CB06/03). Instituto de Salud Carlos III. Spain. 
3. Department of Statistics and Operations Research. University of Seville. Spain. 
4. Research Support Unit. Virgen del Rocio University Hospital. Seville. Spain.  
 Correspondence to: Manuel Ortega-Calvo. Avda. de la Cruz del Campo Nº 36.Bl.1 2ºA. 41005 - Sevilla (Spain). Email: 
ortegacalvo@terra.es 
Received: 2008.09.10; Accepted: 2009.01.29; Published: 2009.01.30 
Abstract 
Objective: We obtained before an explanatory model with six dependant variables: age of 
the patient, total cholesterol (TC), HDL cholesterol (HDL-C), VLDL cholesterol (VLDL-C), 
alkaline phosphatase (AP) and the CA 19.9 tumour marker. Our objective in this study was 
to validate the model by means of the acquisition of new records for an additional analysis. 
Design: Non-paired case control study.  
Setting: Urban and rural hospitals and primary health facilities in Western Andalusia and 
Extremadura (Spain). 
Patients: At both the primary care facilities and hospital level, controls were gathered in a 
prospective manner (n= 275). Cases were prospective and retrospective manner collected 
on (n=126). 
Main outcome measures: Descriptive statistics, logistic regression and bootstrap analysis. 
Results: The AGE (odds ratio 1.02; 95% CI 1.003-1.037) (p= 0.01), the TC (odds ratio 
0.986; 95% C.I. 0.980-0.992) (p< 0.001) and the CA 19.9 (odds ratio 1.023; 95% C.I. 1.012- 
1.034) (p<0.001) were the variables that showed significant values at logistic regression 
analysis and bootstrap. Berkson’s bias was statistically assessed. 
Conclusions: The model, validated by means of logistic regression and bootstrap analysis, 
contains the variables AGE, TC, and CA 19.9 (three of the original six) and has a level 4 over 
5 according to the criteria of Justice et al. (multiple independent validations) [Ann. Intern. 
Med.1999; 130: 515]. 
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Introduction 
Since publication of the work of Rose et al. [1] on 
the relationship between plasma cholesterol and ma-
lignant neoplasia of the colon, there have been multi-
ple bibliographical references for and against this as-
sociation [2-12]. Presently, it is not possible to confirm 
a clear relationship between the appearance of spo-
radic colorectal carcinoma (SCRC) and the diminution 
of the plasma cholesterol or some of its fractions, nor 
have different groups of patients (genetically or 
clinically) been discriminated with SCRC and the ex-
Int. J. Med. Sci. 2009, 6 
 
http://www.medsci.org 
44
istence of the said lipid marker. An abundance of bib-
liographic sources in favour of the prognostic value of 
tumour markers, both in pre-clinical and therapeutic 
phases, exists [13-17]. Carcinoembryonic antigen 
(CEA) is a glycoprotein normally present in plasma in 
very small amounts (on the order of nanograms) that 
increases in the presence of occult adenocarcinomas. 
Its usefulness in colorectal carcinoma [13-14] is well 
described both in the diagnostic phase and in clinical 
follow up [15]. CA 19.9 is a tumour-associated antigen 
that is present in tissues that contain mucin or in the 
circulation, and that is located in the sialylated Lewis 
A blood group antigen [16-18]. The individuals with 
the Lewis a-b genotype cannot synthesize this antigen 
(an approximated 5% of the general population).It 
was first used for the diagnosis and follow up of car-
cinoma of the pancreas, but its usefulness has also 
been demonstrated in SCRC [17-18]. Elevated values 
have also been observed in cases of stomach carci-
noma, carcinoma of the gall bladder and/or biliary 
tract, and hepatomas. Up until now it has not been 
considered as a valid instrument of SCRC screening 
because of its low sensitivity. It should be useful, in-
deed, an instrument that mix these three plasmatic 
markers (cholesterol or its fractions, CEA and CA 
19.9) at early SCRC stages. We published a work pre-
viously on the relationships that could exist between 
both types of substances at the time of the clinical 
appearance of SCRC [18]. We obtained an explanatory 
model with six dependent variables: age of the pa-
tient, total cholesterol (TC), HDL cholesterol (HDL-C), 
VLDL cholesterol (VLDL-C), alkaline phosphatase 
(AP) and the CA 19.9 tumour marker. Our objective in 
this article has been to validate the model by means of 
the acquisition of new records for an additional 
analysis. 
PATIENTS AND METHODS 
The study was designed as a non-paired case 
control study. The new cases and controls has been 
collected over a period of approximately three years 
from both urban and rural hospitals and health cen-
ters in Western Andalusia and Extremadura (Spain). 
The investigators who collected information in the 
health centers (primary care controls) were family 
doctors with more than three years work in their re-
spective facilities. 
The investigators who collected at the hospital 
level (cases and controls) were specialists and training 
residents in internal medicine, neurology, allergy, and 
clinical pharmacology, and also family doctors in 
training o recycling periods. The objectives of the in-
vestigation were explained to all participating physi-
cians and they were provided with record sheets that 
contained the exclusion and inclusion criteria.  
At both the primary care and hospital level, 
controls were gathered in a prospective manner. Only 
one hospital control (Virgen del Rocío University 
Hospital) was retrospective. The primary care con-
trols were collected in the following health centers: 
Pilas (Seville-Rural), Camas (Seville-Rural), Huerta 
del Rey (Seville-Urban) and Mérida (Badajoz-Rural). 
The cases pertaining to this new sampling were gath-
ered in a retrospective manner from the archives of 
the Virgin Macarena and Virgin del Rocío Hospitals of 
Seville, the General Hospital of Mérida and also from 
the Juan Ramon Jiménez Hospital in Huelva by con-
sulting clinical histories, chosen in a random manner, 
over a period of five years (2000-2004).  
The inclusion and exclusion criteria used in this 
part of the study were the same as for the first part of 
the investigation [18]. The diagnostic criteria for in-
clusion of the cases were positive endoscopy and bi-
opsy; those of exclusion were the existence of remote 
metastasis, a severe dislipaemia, coexistence with 
another neoplasia, hereditary polyposis syndrome, 
hereditary non polyposis colorectal cancer, intestinal 
inflammatory disease, non-epithelial neoplasias and 
the immunodeficiency disorders. Consequently 
Dukes’ stage IIA was the maximum SCRC stage seen 
[18]. 
For the controls, the inclusion criterion was the 
absence of SCRC. The exclusion criteria were any type 
of malignant neoplastic disease, existence of 
pre-malignant colorectal lesions, a severe disorder of 
lipid metabolism and the immunodeficiency disor-
ders. Neither colonoscopies nor opaque enemas were 
performed in the controls. Two years after the selec-
tion of the controls in primary care, a complete tele-
phone follow-up was conducted to determine if any 
controls had developed SCRC in the clinical phase. 
The total cholesterol was measured using the 
TECHNICON RA system. The HDL cholesterol was 
measured by the precipitant method. In the original 
sample [18], LDL cholesterol was calculated using the 
Friedewald formula [LDL = TC – HDL – TG/5] 
(where TG = Triglycerides). The VLDL was also cal-
culated using the Friedewald formula [VLDL = 
TG/5]. The TG levels were determined by means of 
colorimetric enzymatic test consisting of enzymatic 
hydrolysis of the TG and the later measurement of 
glycerol by means of colorimetry [18]. CA 19.9 (sialy-
lated Lewis blood group carbohydrate antigen) was 
determined means of a “sandwich” technique similar 
to that used in the measurement CEA [13, 17-18]. 
  The information gathered in this article dates 
from 1992 until 2004. The definitive sample size (n = 
401) was obtained by uniting the original sample [18] 
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with the multicenter sample gathered in this valida-
tion work. Quality control was carried out by two 
different investigators with special interest in the re-
cords gathered by the different collaborators. The fruit 
of that qualitative examination was the rejection of a 
total of 9 controls and 3 cases at the defining moment 
of the construction of the data package. The funda-
mental cause was the lack of fulfilment of the inclu-
sion criteria. The assembly of the previous data 
package with a total of 93 records (53 cases and 40 
controls) in DBase IV format was combined with the 
new data package in an EXCEL format and with a 
total of 308 records was made. The package in EXCEL 
format was exported to SPSS format for its later sta-
tistical analysis, and the quality controls were also 
made at this stage. 
Statistical analysis 
An initial study was made on the set of records 
to obtain centralization and dispersion measures. Ex-
cessive values were considered as outliers; they were 
included in the final quality control because they 
could not be excluded based on the eligibility criteria. 
A normality study of the quantitative variables in the 
combined sample was carried out, including both the 
controls and the cases, by means of the Kolmo-
gorov-Smirnov test [19]. A bivariate analysis was 
made by means of the Mann-Whitney U- test [19]. A 
logistic regression (LR) analysis was carried out and 
did not determine a departure from the model ob-
tained in our previous study [18], with the fact of be-
ing case or control as dependent variable and the 
variables age in years (AGE), total cholesterol (TC), 
HDL fraction (HDL), VLDL fraction (VLDL), alkaline 
phosphatase (AP), and the CA 19.9 marker as predic-
tors [20]. Sample size was taken into account [21]. A 
first analysis was made on the “raw” data package. 
The selection of variables was always backward. In 
the variables in which lost information surpassed 
20%, we decided to impute values by means of the 
SPSS Program (linear interpolation).  
Validity  
  We tried “to repeat” the observational analysis 
of our previous study [18] with the application of 
non-conditional LR to the new data package to vali-
date it in accordance with the criteria of Justice et al 
[22]. In order to appreciate if Berkson’s bias [23] (in-
ternal validity) [24] influenced our observations and 
results, we designed a double study with LR, first 
constructing a statistical model with the controls 
gathered in primary care and the cases, and later, by 
constructing another model with the controls gath-
ered in the hospitals and with the same cases. Finally, 
both models would be compared. If Berkson’s bias 
existed and following the ideas of Feinstein et al, the 
controls gathered in primary care would tend to ele-
vate the odds ratio (OR) in a structural manner in the 
designs of cases and controls [23]. As a final step in 
the validity study, a “bootstrap” analysis was applied 
to the complete sample of cases and controls [25-26]. 
By means of program R the following computer algo-
rithm was applied: 1) Generation of 2000 “bootstrap” 
samples. 2) For each sample, a model of LR was ad-
justed by means of backwards selection, calculating 
the area under the receiver operating characteristic 
curve (ROC). 3) Summary of each one of the set of 
2000 “bootstrap” coefficients [25-26]. 
RESULTS 
  The final sample was composed of a total of 401 
elements (126 cases and 275 controls; control/case 
ratio = 2.18; prospective / retrospective ratio = 4.41). 
Men accounted for 188 (46.9%) and women 213 
(53.1%) of the patients (Pearson’s Chi-square test; p > 
0.05). The centers of origin are shown in Table 1. There 
were no significant differences when contrasting sex 
and center of origin (Pearson’s Chi-square test; 
p>0.05). The descriptive statistic is gathered in Table 
2. 
Table 1. Reference Centers. Data Reference Centers: 1. 
Pilas Health Center (Seville), 2. Mérida Health Center, 
General Hospital of Mérida (Badajoz). 3. Camas Health 
Center (Seville). 4. Virgen Macarena University Hospital 
(VMUH) (Seville) 5. Juan Ramon Jiménez Hospital (Huelva). 
6. Huerta del Rey Health Center (Seville). 7. Virgen del 
Rocío University Hospital (VRUH) (Seville). 
 Center Total
 1 2 3 4 5 6 7  
control 60 36 14 114 32 18 1 275 Var.
case Case 0 12 0 64 5 0 45 126 
Total 60 48 14 178 37 18 46 401 
NOTE: The Pilas Health Center had the VRUH as a hospital refer-
ence center and the Huerta del Rey Health Center had VRUH and 
VMUH. 
Table 2. Estimators of Centralization and Dispersion of 
Continuous Variables. 
 N Mini
mum 
Maxi-
mum 
Average Mean Stan-
dard Error 
Standard 
deviation
AGE 401 24 94 63.42 .744 14.890 
TC 399 81 313 197.70 2.140 42.737 
HDL 346 17 176 45.65 .925 17.202 
LDL 191 38 235 131.68 2.508 34.656 
VLDL 228 10 216 54.90 3.617 54.623 
TG 264 25 566 121.21 4.276 69.482 
AP 357 29 500 154.67 4.292 81.104 
CA19_9 380 .1 162.0 19.938 1.2423 24.2168 
AGE-age in years; TC- total cholesterol; HDL-high density lipo-
protein; LDL-low density lipoprotein; VLDL-very low density 
lipoprotein; TG-triglycerides; AP-alkaline phosphatase. 
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The values obtained for the Kolmo-
gorov-Smirnov test (study of normality of continuous 
variables) are shown in Table 3. 
Table 3. Normality Analysis of the Continuous Variables. 
Kolmogorov-Smirnov test for a sample. 
 N Normal Parameters 
(a,b) 
Z of Kol-
mogoro & 
Smirnov 
Sig. asin-
totic. 
(bilateral)
  Media Standard 
deviation 
  
AGE 401 63.42 14.890 1.496 * .023 
TC 399 197.70 42.737 .649 .794 
HDL 346 45.65 17.202 2.227 * .000 
LDL 191 131.68 34.656 1.075 .198 
VLDL 228 54.90 54.623 4.664 * .000 
TG 264 121.21 69.482 2.543 * .000 
AP 357 154.67 81.104 1.146 .145 
CA19_9 380 19.938 24.2168 4.035 * .000 
a. The distribution of contrast is Normal. 
b. Calculated from the data. 
AGE-age in years; TC- total cholesterol; HDL-high density lipo-
protein; LDL-low density lipoprotein; VLDL-very low density 
lipoprotein; TG-triglycerides; AP-alkaline phosphatase. (* signifi-
cant values – non normal variables - see discussion). 
 
 
Table 4 shows the application of the 
Mann-Whitney U-test to the continuous variables to 
study differences between the distributions between 
the cases and controls. The adjustment of the 
non-conditional logistic regression model, on the total 
data set, is shown in Table 5. The same type of analy-
sis, but with the primary care and hospital controls 
are shown in Tables 6 and 7, respectively. The inter-
action [CA 19.9 x AGE] is in Table 8. The “bootstrap” 
analysis is shown in Figures 1 and 2. The HDL, LDL, 
and VLDL variables were dealt with by imputed val-
ues (HDL-1, VLDL-1 and LDL-1) because the loss of 
information was superior to 20% (linear interpolation 
- SPSS). 
 
Table 4. Statistics of contrast (a) for comparison of con-
tinuous variables, according to whether cases or controls. 
  Mann-Whitney U-test Sig. asintotic. (bilateral) 
AGE 14285.500 * .005 
TC 10815.500 .* 000 
HDL 7097.000 * .000 
LDL 1835.000 .* 000 
VLDL 2881.500 .* 000 
TG 7779.500 .154 
AP 14037.000 .702 
CA19_9 10417.500 * .000 
AGE-age in years; TC- total cholesterol; HDL-high density lipo-
protein; LDL-low density lipoprotein; VLDL-very low density 
lipoprotein; TG-triglycerides; AP-alkaline phosphatase. (* signifi-
cant values). 
Table 5. Final Model Adjusted with Raw Values. 
 B Wald Degree 
of free-
dom (df) 
Sig. Exp(B) 95.0% C.I. for 
EXP(B) 
            Lower Upper
Step 
1(a)
AGE .020 5.563 1 .018 * 1.020 1.003 1.037 
  TC -.014 19.695 1 .000 * .986 .980 .992 
  CA19_9 .023 17.946 1 .000 * 1.023 1.012 1.034 
  Constant .073 .009 1 .926 1.076     
AGE-age in years; TC- total cholesterol. (* odds ratios). 
Table 6. Logistic regression made with hospital cases and 
controls of primary care. 
95.0% C.I. for 
EXP(B) 
 B S.E. Wald df Sig. Exp(B)
Lower Upper
AGE .035 .010 11.420 1 .001 * 1.036 1.015 1.057 
TC -.017 .004 17.891 1 .000 * .983 .975 .991 
CA19_9 .045 .010 19.738 1 .000 * 1.046 1.026 1.067 
Step 
1(a) 
Constant .267 .973 .075 1 .784 1.306     
AGE-age in years; TC- total cholesterol. (* odds ratios). 
 
Table 7. Logistic regression made with hospital cases and 
controls. 
95.0% C.I. for 
EXP (B) 
 B S.E. Wald df Sig. Exp 
(B) 
Lower Upper
AGE .013 .009 1.888 1 ** 
.169 
* 
1.013
.994 1.032 
TC -.012 .003 12.475 1 .000 * 
.988 
.982 .995 
CA19.9 .015 .005 7.393 1 .007 * 
1.015
1.004 1.026 
Step 
1(a) 
Constant .892 .887 1.011 1 .315 2.440     
AGE-age in years; TC- total cholesterol. (* odds ratios). (** non 
significant values – Berkson´s biass assessment – Feinstein et al. 
1986. [23]). 
 
Table 8. Logistic regression with the variable interaction 
(CA19.9 x AGE). Cases and controls of primary care and 
hospital. 
95.0% C.I. for 
EXP (B) 
 B S.E. Wald df Sig. Exp 
(B) 
Lower Upper
AGE .049 .013 14.486 1 .000 * 
1.051
1.024 1.078 
CA19.9 .129 .036 12.687 1 .000 * 
1.138
1.060 1.222 
TC -.013 .003 18.409 1 .000 * 
.987 
.981 .993 
CA19.9xAGE .002 .001 9.391 1 .002 * 
.998 
.997 .999 
Step 
1(a)
Constant - 
2.035
1.064 3.656 1 .056 * 
.131 
    
AGE-age in years; TC- total cholesterol. (* odds ratios). 
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Figure 1. 2000 bootstrap values of Area under the ROC 
Curve. 
 
 
 
 
 
 
 
 
Figure 2. 2000 bootstrap coefficients. AGE-age in years; 
TC- total cholesterol; TG-triglycerides; AP-alkaline phos-
phatase; LDL-low density lipoprotein; VLDL-very low den-
sity lipoprotein; HDL-high density lipoprotein. 
 
DISCUSSION 
  We have made an investigation to try to vali-
date a multivariate explanatory model of the diagno-
sis of SCRC in Dukes’ stages I and IIa using 
non-conditional logistic regression and “bootstrap” 
analyses. The original model with six variables was 
published [18] and was the departure point for the 
accomplishment of this work. The new sample size 
was included 401 elements and was composed of 126 
cases and 275 controls. The design was non-paired. A 
total of 308 new records pertain to the validation 
phase of the work. The original sample was gathered 
entirely in the Virgen Macarena University Hospital 
of Seville (VMUH) from 1992 to 1995 in a prospective 
manner. From the validation phase, 11 cases and 74 
controls of the sample also pertain to this center. The 
new cases were compiled in a retrospective manner 
from the general archives of clinical histories, always 
respecting the inclusion criteria (period 2000-2004), 
and the new controls were gathered in a prospective 
manner in the Internal Medicine Service during 2003. 
From 2001 to 2003, the rest of the cases and controls in 
this investigation were collected in the centers of ori-
gin (Table 1). Therefore, the time limits of our data 
collection were from 1992 to 2004. Throughout this 
time, the inclusion and exclusion criteria were scru-
pulously respected. The general ratio of prospective / 
retrospective elements was 4.41/1, which we found 
acceptable. Each health center and each hospital were 
connected to each other in such a way that the users of 
the primary care centers were admitted in the tertiary 
care centers, thereby fulfilling a precept of 
case-control studies. The ratio between these was 2.18 
controls for each case, which has a level of acceptable 
internal efficiency with regard to design.  
The descriptive results of the complete data 
package are shown in Table 2. Among them, it is pos-
sible to highlight the arithmetic means of the cases 
that are lower than those of the controls with regard 
to the lipid variables referred to, except for the 
triglycerides. After the application of the Kolmo-
gorov-Smirnov test, it was possible to consider the 
variables: TC (n = 399), LDL (n = 191), and AP (n = 
357) as normal (Table 3). For the rest of the variables, 
the null hypothesis of normal distribution was re-
jected [19]. 
There was no significant difference in the dis-
tribution by sex between the cases and the controls 
(Pearson’s Chi-Square test, p = 0.20). Neither was 
there a significant difference found in the distribution 
by sex and reference centers (Pearson’s Chi-Square 
test, p = 0.26). We believe that these results show the 
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sample to be representative and do not demonstrate 
origin imbalances. We applied non-conditional LR to 
try to obtain a model adjusted with the new sample 
size by means of the backward selection of variables. 
As mentioned previously, the program used was 
SPSS. We could obtain a new model that contained 
the AGE variable, the CA19.9 variable, and the TC 
(total cholesterol) variable. Thus, three of the six 
original variables (Table 5) [18] could enter in the new 
model. That was a quite acceptable result for us be-
cause it conserved half of the predictors and because it 
was “coherent” with the clinical and biological reality. 
The age and CA 19.9 were “predisposing” for the 
condition with OR’s of 1.020 and 1.023 respectively 
and the rate of total cholesterol adopted an opposite 
direction with an OR of 0.986, all of them reaching 
statistical significance (p<0.05). It is possible to affirm 
that this adjusted and definitive model has displayed 
a level of validity of 4 over 5 according to the criteria 
of Justice et al. [22] because it contains multiple inde-
pendent validations. 
The clinical and biological value of CA 19.9 is a 
fact stated previously in the bibliography [17, 18]. Its 
elevation is much more frequent in malignant proc-
esses than in benign ones, above all in pancreatic, co-
lorectal, pulmonary, liver, and ovarian neoplasias. A 
very interesting piece of evidence for the control of 
the classification bias of this article (with regard to the 
selection of the controls) has been shown in the work 
Varol et al [27], where the normality of CA 19.9 in 
patients with chronic cardiac insufficiency was dem-
onstrated. In other publications, CA 19.9 has not 
shown as much diagnostic capacity for SCRC when 
attempting to include it in multivariate models [28]. In 
this investigation, CEA was not included as an ex-
planatory variable because it did not form part of the 
original model [18].  
Another very interesting work on the impor-
tance of plasma lipid levels in SCRC is that of Notar-
nicola et al [29], in which an association was found 
between the capacity to develop to metastasis and 
elevated levels of TC and LDL in patients with SCRC. 
Those findings are consistent with our results because 
a selection criterion of the cases was that no remote 
metastasis had developed (Dukes’ stage IIA at the 
most). Our cases tend to present with low lipids. We 
preferred the Dukes classification [18] to the As-
tler-Coller [30] classification because of the long pe-
riod of data collection of our investigation and be-
cause it was the one that we used from the beginning. 
Notarmicola et al. have also published very sugges-
tive findings on the enzymatic changes in the meva-
lonate pathway in patients with SCRC depending on 
the location of the tumour in the large intestine [31].  
  The use of LR for the observational studies 
continues to being authenticated by the bibliography, 
showing similar results if it is compared with the 
propensity scores [32] or with the artificial neural 
networks [33]. The use of a method of manual selec-
tion of variables is a fact also more and more stated in 
the bibliography, mainly if the multivariate model is 
complemented later with “bootstrapping” as it was in 
our study [34].  
When two different models were generated, the 
first made with controls gathered in primary care 
along with all the cases, and the second made with the 
controls gathered in the hospitals and the same cases, 
the first showed significant values in the three pre-
dictors studied whereas the second only showed them 
in two of these. First was more efficient and it had 
higher OR’s than the second, as Feinstein et al [23] 
predicted when studying the epidemiological nature 
of Berkson’s bias (Tables 6 and 7). 
The exploration of interactions showed a sig-
nificant result in the AGE x CA 19.9 (p<0.005) variable 
(Table 8). The predisposing effect for the condition 
was potentiated for both variables at the individual 
level (OR of 1.051 for AGE and OR of 1.138 for CA 
19.9) with respect to the model obtained with raw 
values, but the OR of the variable interaction (AGE x 
CA 19.9) had an opposite direction. Greenland [35] 
provides an explanation on the fact that, as in our 
model of interaction, the coefficient of the product 
variable is different from those of the individually 
contemplated variables. The coefficient of the interac-
tion variable reflects only the net balance between the 
different types of answer implied in the interaction. A 
coefficient > 0 only implies that the synergistic an-
swers are more frequent than the antagonistic and the 
competitive answers, but not that these latter ones are 
absent. A coefficient < 0 only implies that the antago-
nistic and competitive answers are more frequent 
than the synergistic, but not that these latest ones do 
not exist. A coefficient = 0 implies that the synergistic 
answers are balanced with the antagonistic and com-
petitive answers, but not that the interactions are ab-
sent. 
Using program R, 2000 “bootstrap” samples 
were generated from the real data with using the six 
variables of the original model, considering the vari-
ables HDL, VLDL, and LDL in their versions with 
imputed values HDL-1, VLDL-1 and LDL-1. The co-
efficients obtained by means of non-conditional LR 
with the method of backward selection of variables 
were studied. The AGE, the TC, and CA 19.9 were 
also the variables that showed significant values 
(Figures 1 and 2). Although upper limit of the TC 
confidence interval reaches to null (Figure 2) we ac-
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cept it like a significant value. VLDL_1 is a quite line-
arly built variable at this research and so we do not 
give any importance to its bootstrap analysis (Figure 
2). The results obtained for the area under the ROC 
curve (AUC) were also very interesting, the box figure 
shows that more than half of the values are superior to 
0.9 (Figure 1) (in fact they are extraordinary ; we have 
checked them several times). . These findings grant in 
the first place a high degree of internal validity to our 
work and give strength to our observations. Although 
“bootstrapping” is not a technique of measurement of 
external validity, it is one of internal validity, which in 
epidemiological terms is prior to the external [22, 24, 
36].  
In short, we have obtained an explanatory model 
of malignant sporadic neoplasia of the colon in Dukes’ 
stages I and IIA by means of validation of a previous 
original model [18]. The model, validated by means of 
logistic regression and “bootstrap” analysis, contains 
the variables AGE [18], TC [1,3-6] and CA 19.9 [17, 
37-39] (three of the original six) and has a level 4 over 
5 according to the criteria of Justice et al. [22] (it means 
multiple independent validations). The existence of 
Berkson’s bias has been statistically assessed [23].  
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